Ann Pharmacol Pharm | Volume 2, Issue 4 | Research Article | Open Access
B Perissutti1*, G Zingone1, L Lassiani1, M Moneghini1 and E Franceschinis2
1Department of Chemical and Pharmaceutical Sciences, University of Trieste Italy
2Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy
*Correspondance to: B Perissutti
Fulltext PDFThe aim of the present investigation is to produce rapidly disintegrating laminar extrudates for delivering ibuprofen in the mouth of paediatric patients. This laminar shape is particularly convenient for drug delivering in the mouth and can be easily cut in cut in different sizes allowing for a convenient adjustment of the drug dose depending on the age of the patient. Due to the fact that in paediatric formulations, the selection of the excipients is always a challenging issue and the reduction of their amount is always highly desirable, in this study to select the most appropriate composition to achieve a rapid disintegration and simultaneously permit a high amount of ibuprofen in the system, an experimental design for mixtures was employed and the disintegration time in simulated saliva was used as experimental response. In addition, after solid state analyses to check possible insurgence of drug-excipients interactions, laminar extrudates were characterised in terms of mechanical properties and in vitro dissolution performances. Extrudates with the desired uniform laminar shape, constant thickness (2 mm) and a very high content of drug (82% wt) were produced. These products exhibited a short disintegration time. The dose for a patient of 6-12 years corresponded to a length of extrudate between 1-1.5 cm, perfectly compatible with a formulation orodispersible thin laminar extrudate intended for a paediatric patient (Figure 1).
Paediatric formulation; Flexible formulation; Orodipersible formulation; Excipients; Disintegration
B.Perissutti, G Zingone, L Lassiani, M Moneghini, E Franceschinis. Rapidly- Disintegrating Laminar Extrudates: Preliminary Experiments upon an Age Appropriate Pediatric Formulation. Ann Pharmacol Pharm. 2017; 2(4): 1042.